China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co., Ltd., a dual-headquartered oncolytic virus company based in Vancouver, Canada, and Shanghai, China. The partnership will evaluate the combination of Akeso’s ivonescimab, a PD-1/VEGF bispecific antibody, and Virogin’s VG201, a CEA-targeted oncolytic virus, in an open-label, multi-center Phase Ib/II study for advanced colorectal cancer with liver metastases (CRLM). Akeso will lead clinical execution, leveraging its extensive oncology development expertise.
Therapeutic Agents and Mechanisms
Ivonescimab, approved in China in May 2023 for EGFR-mutant non-squamous NSCLC, is a first-in-class bispecific antibody that combines PD-1 immune checkpoint inhibition with VEGF angiogenesis inhibition. VG201 is a novel HSV-1-based oncolytic virus designed to selectively lyse tumors overexpressing carcinoembryonic antigen (CEA) while secreting immune-stimulating cytokines IL-12 and IL-15/IL-15Rα. This dual action aims to remodel the immunosuppressive tumor microenvironment, enhancing anti-tumor immune responses.
Clinical Trial and Future Outlook
The Phase Ib/II study will assess the safety and efficacy of the ivonescimab-VG201 combination in patients with advanced colorectal cancer and liver metastases. Preclinical data have demonstrated favorable safety profiles and preliminary anti-tumor activity in colorectal cancer models. This collaboration highlights the potential of combining bispecific antibodies with oncolytic viruses to address unmet medical needs in oncology.-Fineline Info & Tech
